Sachiko Ozawa

Sachiko Ozawa

Auto-generated profile, based on publicly available information

Sachiko Ozawa

Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SBSarah M Bartsch
Sarah M Bartsch
BLBenjamin A Lopman
Benjamin A Lopman
SOSachiko Ozawa
Sachiko Ozawa
AHAron J Hall
Aron J Hall
BLBruce Y Lee
Bruce Y Lee
Despite accounting for approximately one fifth of all acute gastroenteritis illnesses, norovirus has received comparatively less attention than other infectious pathogens. With several candidate vaccines under development, characterizing the global economic burden of norovirus could help funders, policy makers, public health officials, and product developers determine how much attention and resources to allocate to advancing these technologies to prevent and control norovirus. We developed a computational simulation model to estimate the economic burden of norovirus in every country/area (233 total) stratified by WHO region and globally, from the health system and societal perspectives. We considered direct costs of illness (e.g., clinic visits and hospitalization) and productivity losses. Globally, norovirus resulted in a total of $4.2 billion (95% UI: $3.2–5.7 billion) in direct health system costs and $60.3 billion (95% UI: $44.4–83.4 billion) in societal costs per year. Disease amongst children <5 years cost society $39.8 billion, compared to $20.4 billion for all other age groups combined. Costs per norovirus illness varied by both region and age and was highest among adults ≥55 years. Productivity losses represented 84–99% of total costs varying by region. While low and middle income countries and high income countries had similar disease incidence (10,148 vs. 9,935 illness per 100,000 persons), high income countries generated 62% of global health system costs. In sensitivity analysis, the probability of hospitalization had the largest impact on health system cost estimates ($2.8 billion globally, assuming no hospitalization costs), while the probability of missing productive days had the largest impact on societal cost estimates ($35.9 billion globally, with a 25% probability of missing productive days). The total economic burden is greatest in young children but the highest cost per illness is among older age groups in some regions. These large costs overwhelmingly are from productivity losses resulting from acute illness. Low, middle, and high income countries all have a considerable economic burden, suggesting that norovirus gastroenteritis is a truly global economic problem. Our findings can help identify which age group(s) and/or geographic regions may benefit the most from interventions.

1 February 2016 in Health Affairs
Verified
Journal Article
Open access
PDF file
SOSachiko Ozawa
Sachiko Ozawa
SCSamantha Clark
Samantha Clark
Allison PortnoyAllison Portnoy
Allison Portnoy
SGSimrun Grewal
Simrun Grewal
LBLogan Brenzel
Logan Brenzel
DWDamian G. Walker
Damian G. Walker
An analysis of return on investment can help policy makers support, optimize, and advocate for the expansion of immunization programs in the world’s poorest countries. We assessed the return on investment associated with achieving projected coverage levels for vaccinations to prevent diseases related to ten antigens in ninety-four low- and middle-income countries during 2011–20, the Decade of Vaccines. We derived these estimates by using costs of vaccines, supply chains, and service delivery and their associated economic benefits. Based on the costs of illnesses averted, we estimated that projected immunizations will yield a net return about 16 times greater than costs over the decade (uncertainty range: 10–25). Using a full-income approach, which quantifies the value that people place on living longer and healthier lives, we found that net returns amounted to 44 times the costs (uncertainty range: 27–67). Across all antigens, net returns were greater than costs. But to realize the substantial positive return on investment from immunization programs, it is essential that governments and donors provide the requisite investments.

3 August 2018 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
SOSachiko Ozawa
Sachiko Ozawa
DEDaniel R. Evans
Daniel R. Evans
SBSophia Bessias
Sophia Bessias
DHDeson G. Haynie
Deson G. Haynie
TYTatenda T. Yemeke
Tatenda T. Yemeke
JHJames E. Herrington
James E. Herrington
Increasing access to essential medicines is integral to the effort to reduce global morbidity and mortality.1 While access and health outcomes have generally improved in recent decades, these efforts face a serious obstacle from the threat of substandard and falsified (SF) medicines.2-4 Poor-quality medicines increase risks of morbidity and mortality by prolonging illnesses and heighten the risk of treatment failure, poisoning, and adverse drug interactions.5,6 Circulation of SF medicines with little clinical effectiveness also places entire communities at risk of drug resistance, posing a threat to global treatment effectiveness, as well as undermining people’s overall trust in the health system and its legitimate health care professionals.5-9 Over time, diminished trust in licensed health care professionals may further encourage informal care-seeking and self-medication.10 Poor health outcomes can also erode trust in the manufacturers of genuine pharmaceutical products, which are often challenging to distinguish from SF ones without the use of verification technologies.11

1 August 2013 in Social Science & Medicine
Verified
Journal Article
Closed access
SOSachiko Ozawa
Sachiko Ozawa
PSPooja Sripad
Pooja Sripad

1 December 2012 in Vaccine
Verified
Journal Article
Closed access
SOSachiko Ozawa
Sachiko Ozawa
AMAndrew Mirelman
Andrew Mirelman
MSMeghan L. Stack
Meghan L. Stack
DWDamian G. Walker
Damian G. Walker
OLOrin S. Levine
Orin S. Levine

8 August 2013 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
PDF file
SOSachiko Ozawa
Sachiko Ozawa
MSMeghan L Stack
Meghan L Stack
Vaccines save millions of lives every year. They are one of the safest and most effective public health interventions in keeping populations healthy while bringing numerous social and economic benefits. Vaccines play an important role in ensuring that children, regardless of where they live, can have a healthy start to life. New financing mechanisms that allow poorer countries to gain access to vaccines faster than ever mean additional deaths and disabilities are projected to be saved during the Decade of Vaccines (2011–2020). Trust in vaccines and in the health system is an important element of public health programs that aim to deliver life-saving vaccines. Indeed, understanding the contributors and threats to trust is essential to explaining vaccine acceptance, particularly as they vary across epidemiologic conditions, specific vaccines and cultural and sociopolitical settings. Greater efforts to communicate the benefits and risks of vaccines and address issues with evidence-based information will help improve and sustain public trust in vaccines and health systems worldwide. Measuring and monitoring trust levels and focusing on deliberate efforts to build trust in vaccines are important steps to reducing vaccine confidence gaps when they occur.